London, UK (PRWEB) December 05, 2013
Market Publishers Ltd is happy to announce a special discount offer on Pharma Country Series produced by GlobalData.
Do not wait until the offer expires! Grab the excellent opportunity right now!
Stay one step ahead of the constantly intensifying competition by gaining a comprehensive understanding of the rapidly-changing landscape of global pharma market with the help of GlobalData research studies now available at discounted prices!
Different Countries Pharma Market Research Reports on Offer Include but Are not Limited to:
PharmaPoint: Non-Small Cell Lung Cancer - UK Drug Forecast and Market Analysis to 2022. Non-Small Cell Lung Cancer (NSCLC) is known as the most common lung cancer worldwide and also as the 2nd common cancer in women and men. Historically, chemotherapy was the key paradigm for NSCLC treatment. However, the overall NSCLC landscape has recently been fragmented into smaller niche patient population due to introduction of the novel targeted therapies designed for patients with some specific biomarkers. Increasing prevalence of NSCLC in tandem with the planned launches of multiple new premium-priced drugs is forecast to boost the growth of the UK NSCLC market in the offing. The report contains a comprehensive disease profile of NSCLC, discloses valuable information on the key drugs available in the UK, and also uncovers historical, present and forecast data on the NSCLC industry performance …
PharmaPoint: Dry Eye Syndrome - US Drug Forecast and Market Analysis to 2022. Dry eye syndrome (DES) is the most common reason for elderly population’s need for eye care. The demand for novel DES therapies will rise exponentially in the US driven by the rapidly-aging population in the country. The domestic DES market growth is also likely to be spurred by ongoing advancements in the DES therapy, introduction of the treatment options and drugs, expanding potential patients pool and enhancing physician awareness of the disease. The study presents an insightful overview of the landscape of the US DES market, contains essential data on the disease gathered in a detailed profile, reviews the currently available drugs in the country, provides a snapshot of the most recent industry developments, examines the key factors influencing the market growth as well as outlines market future growth prospects …
PharmaPoint: Psoriasis - Spain Drug Forecast and Market Analysis to 2022. The lack of the long-term and effective therapies for Psoriasis (PsO) is one of the burgeoning issues worldwide. The Spanish PsO market is still considered to be conservative due to the uncertain economic situation in the country. However, the domestic market is poised to witness positive growth in the years to come. Such brands as Enbrel, Humira and Remicade are expected to lead the PsO market in Spain through 2022. The research report grants access to a valuable information on the Spanish PsO market performance. It highlights the most recent industry developments, covers the existing products, delves into the competitive landscape, reviews the leading brands and also provides a comprehensive disease profile. The study analyzes the major forces shaping the market, uncovers drug sales statistics, traces the most recent events related to the industry and, furthermore, offers market future outlook along with drug sales projections …
The offer is valid till December 30, 2013!
For a full list of GlobalData country pharma market research reports on offer, please click here.